6',7'-Epoxybergamottin is primarily studied for its role in inhibiting cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of many drugs. This property makes it significant in the field of pharmacology, where it is investigated for its potential to alter drug bioavailability and pharmacokinetics. By inhibiting CYP3A4, it can lead to increased plasma concentrations of certain medications, thereby affecting their efficacy and safety. This interaction is particularly relevant in the context of grapefruit juice consumption, as 6',7'-Epoxybergamottin is one of the compounds responsible for the "grapefruit juice effect," where the juice can enhance the effects of some drugs. Additionally, it is explored for its potential anticancer properties, as it may interfere with the metabolic activation of certain carcinogens. Research is ongoing to further understand its mechanisms and applications in drug development and cancer therapy.